Precision Drilling
PDS
Lantheus
LNTH
eBay
EBAY
4
DexCom
DXCM
5
Collegium Pharmaceutical
COLL
US Stock MarketDetailed Quotes
TVGN Tevogen Bio Holdings
- 1.080
- -0.120-10.00%
Close Mar 31 16:00 ET
- 1.090
- +0.010+0.93%
Pre 08:40 ET
189.06MMarket Cap-13.50P/E (TTM)
1.180High1.080Low469.33KVolume1.170Open1.200Pre Close527.02KTurnover3.54%Turnover RatioLossP/E (Static)175.05MShares3.09052wk High-14.59P/B14.32MFloat Cap0.25652wk Low--Dividend TTM13.26MShs Float21.090Historical High--Div YieldTTM8.33%Amplitude0.256Historical Low1.122Avg Price1Lot Size
Market Insights
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
Tevogen Bio Holdings Stock Forum
Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast
Wednesday, 26th March at 3:12 pm
WARREN, N.J., March 26, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio("Tevogen Bio Holdings Inc." or "Company") (NASDAQ: TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, is pleased to share that Founder and CEO, Ryan Saadi,...
Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO
Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO
Monday, 10th March at 12:40 pm
• Vaccine is intended to stimulate T cell responses against targets across the entire genome of the selected virus, similar to company's lead product candidate TVGN 489, to mitigate the risk posed by mutations.
• Approach may provide prophylaxis to viral infections and would be complementary to current treatment under development by Te...
No comment yet